ArticleFrontiers in medicine2026
Postpartum-onset anti-PM/Scl-positive dermatomyositis-systemic sclerosis overlap syndrome with reversible interstitial lung disease: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Polymyositis-scleroderma autoantibody (Anti-PM/Scl) associated connective tissue disease is a recognized overlap syndrome classically characterized by features of polymyositis- systemic sclerosis overlap. However, presentation with a dermatomyositis (DM) phenotype accompanied with interstitial lung disease (ILD) is less commonly reported. Pregnancy and the postpartum period are recognized immunological triggers for overlap syndromes, potentially leading to autoimmune disease. Postpartum-onset inflammatory myopathy with overlap features and significant pulmonary involvement poses substantial diagnostic challenges due to its heterogeneous clinical presentation and evolving serologic profiles. Case presentation: We present a case of a 25-year-old Palestinian woman presenting with progressive proximal muscle weakness, characteristic dermatomyositis cutaneous manifestations, notable unintentional weight loss, and systemic symptoms 4 months postpartum. Laboratory tests showed markedly elevated creatine kinase and positive antinuclear antibodies, positive anti-PM/Scl antibodies and positive anti-dsDNA antibodies, while anti-U1-RNP antibodies were negative. Imaging demonstrated hepatomegaly and splenomegaly, and pulmonary function testing showed interstitial lung disease (ILD). Muscle biopsy confirmed inflammatory myopathy without typical perifascicular atrophy. The patient showed incomplete clinical response to treatment with corticosteroids and mycophenolate mofetil; however, transitioning to rituximab resulted in substantial clinical, pulmonary, and functional improvement. Conclusion: This case illustrates a diagnostically challenging presentation of postpartum-onset Anti-PM/Scl-Positive dermatomyositis-systemic sclerosis overlap syndrome complicated by ILD and multisystem involvement. It underscores the diagnostic challenges associated with overlap syndrome and connective tissue disease phenotypes, and supports the potential effectiveness of rituximab in refractory overlap myositis and reversing inflammatory ILD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.